Revive Therapeutics Ltd (RVVTF)

[RioDad]

Only 3 posts left for today, like Time Outs, I can’t take them with me!

So, I might as well use them.

I think we’ve seen Psilocybin based money flow in, and a few probably hedged a few more shares because of the low price AND the Covid play.

So let’s REPLAY the non-Covid platforms available to Revive Therapeutics for anyone who maybe new here.

1) Orphan drug status for a CBD drug
2) Non-synthetic “Shroom” stance, and both R&D & supply agreements in place
3) Bucillamine P3 trial seems to be the first step towards a larger market for Pulmonary & Cardiac Inflammation diseases.
4) Oral Thin Strips, in my opinion, this is the biggest potential money maker (patent pending) Revive holds currently. This product will help ensure psilocybin (and other psychedelic drugs) micro dosing, and be an easier and faster transporter for absorption and greater effectiveness. Other companies will want to license this technology from RVVTF.

All told outside of the Covid play, RVVTF has some tools in its belt to rake in between $5-10B over the next 10 years. Which means RVVTF is a $4-8 stock within 2-3 years without the Covid-19 Bucillamine approval.